JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 178 filers reported holding JUNO THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 1.38 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $348,841,000 | -16.8% | 7,631,631 | -18.4% | 35.74% | -38.7% |
| Q3 2017 | $419,387,000 | -19.3% | 9,348,799 | -46.2% | 58.30% | -16.2% |
| Q2 2017 | $519,553,000 | +35.0% | 17,382,192 | +0.2% | 69.60% | -1.2% |
| Q1 2017 | $384,969,000 | +17.7% | 17,348,799 | 0.0% | 70.44% | -13.7% |
| Q4 2016 | $327,025,000 | -37.2% | 17,348,799 | 0.0% | 81.61% | +23.6% |
| Q3 2016 | $520,637,000 | -21.9% | 17,348,799 | 0.0% | 66.02% | -34.0% |
| Q2 2016 | $666,888,000 | +2.0% | 17,348,799 | 0.0% | 100.00% | 0.0% |
| Q1 2016 | $653,858,000 | -42.3% | 17,348,799 | -33.1% | 100.00% | 0.0% |
| Q4 2015 | $1,132,937,000 | +7.3% | 25,948,799 | 0.0% | 100.00% | 0.0% |
| Q3 2015 | $1,055,857,000 | -23.8% | 25,948,799 | -0.2% | 100.00% | 0.0% |
| Q2 2015 | $1,385,983,000 | -15.6% | 25,988,799 | -4.0% | 100.00% | 0.0% |
| Q1 2015 | $1,642,947,000 | +16.2% | 27,084,525 | 0.0% | 100.00% | 0.0% |
| Q4 2014 | $1,414,354,000 | – | 27,084,525 | – | 100.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 1,864,174 | $85,211,000 | 94.86% |
| Crestline Management, LP | 7,631,631 | $348,841,000 | 35.74% |
| Omega Fund Management, LLC | 753,564 | $34,445,000 | 24.90% |
| DDD Partners, LLC | 191,458 | $8,752,000 | 3.40% |
| SIB LLC | 100,000 | $4,571,000 | 3.28% |
| PECONIC PARTNERS LLC | 433,587 | $19,819,000 | 2.85% |
| Cormorant Asset Management, LP | 550,000 | $25,141,000 | 2.63% |
| ARK Investment Management | 682,495 | $31,197,000 | 2.48% |
| BB BIOTECH AG | 1,925,000 | $87,992,000 | 2.48% |
| Clarius Group, LLC | 120,988 | $5,530,000 | 2.47% |